Complementary Molecular and Metabolic Characterization of Meningiomas With DOTATATE and FDG-PET: Advancing Treatment Planning and Prognostication

Clin Nucl Med. 2019 Jan;44(1):e26-e27. doi: 10.1097/RLU.0000000000002328.

Abstract

Ga-DOTATATE imaging for meningiomas is gaining clinical use for selecting patients that may benefit from targeted therapy (eg, Lu-DOTATATE). We present an image of a 67-year-old man with an intracranial WHO grade III anaplastic meningioma. He underwent tumor resection followed by intensity-modulated radiation therapy but experienced a recurrence 25 months later. He received an F-(FDG) and Ga-DOTATATE PET/MR to evaluate for the presence of somatostatin receptor expression and guide subsequent treatment. The scans showed both concordant and discordant regions of uptake, indicating that high somatostatin receptor (SSTR2) expression may not coincide with areas of increased metabolic rate.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Fluorodeoxyglucose F18
  • Humans
  • Male
  • Meningeal Neoplasms / diagnostic imaging*
  • Meningioma / diagnostic imaging*
  • Octreotide / analogs & derivatives
  • Organometallic Compounds
  • Positron Emission Tomography Computed Tomography*
  • Radiopharmaceuticals

Substances

  • Organometallic Compounds
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
  • lutetium Lu 177 dotatate
  • Octreotide